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Abstract We have previously generated transgenic (Tg) mice
expressing the human apolipoprotein (apo) A-I/C-III/A-IV gene
cluster. This expression induced hyperlipidemia but reduced
atherosclerotic lesions in genetically modified mice lacking apoE.
Atherosclerosis is a multifactorial process and environmental
factors such as diet play significant roles in its development. We
examined here how an atherogenic diet influences the expression
of the human genes and the characteristics of the Tg mice. Our
results indicate that a high fat-high cholesterol diet up-regulates
the intestinal expression of the three genes and the concentration
of the three proteins in plasma. Cholesterol concentration was
highly increased in the non-high density lipoprotein (HDL)
fraction, and less, although significantly, in the HDL fraction.
Tgs showed a 65% reduction in diet-induced aortic lesions
compared with non-Tg mice. Atherogenic diet increases the
expression of the genes encoding the scavenger receptor class B
type I (SR-BI) and ATP binding cassette transporter 1 (ABCA1)
proteins. As cholesterol efflux mediated by SR-BI or by ABCA1
was enhanced in Tg mice fed an atherogenic diet, we can
hypothesize that increased reverse cholesterol transport is the
basis of the protective mechanism observed in these animals. In
conclusion, we present evidence that the expression of the human
gene cluster in mice protects against atherogenesis in response to
an atherogenic diet. ß 2001 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
Key words: Apolipoprotein; Atherosclerosis ;
Transgenic mouse; Atherogenic diet ; Cholesterol e¥ux
1. Introduction
Coronary heart disease (CHD), the principal cause of mor-
tality in the developed countries, is mainly caused by athero-
sclerosis. The atherogenic process is known to be strongly
in£uenced by lipoprotein metabolism, and the association be-
tween low high density lipoprotein (HDL) concentration and
premature atherosclerosis is well known [1]. Two important
protein components of HDLs are apolipoproteins (apo) A-I
and A-IV. Their genes are grouped together with the gene of
apoC-III in a cluster of 17 kb on human chromosome 11 [2].
ApoA-I and apoA-IV have essential roles in the reverse cho-
lesterol transport (RCT) pathway [3], and their overexpression
protects against atherosclerosis [4^7]. ApoC-III, by inhibiting
triglyceride-rich lipoprotein catabolism, induces hypertrigly-
ceridemia [8], and its overexpression results in increased athe-
rosclerosis [9,10]. In humans, a DNA inversion within the
apoA-I/C-III/A-IV-encoding gene cluster causes premature
atherosclerosis [11]. In family studies, familial apoA-I/C-III/
A-IV de¢ciency has been associated with premature athero-
sclerosis [12], and genetic variations of the gene cluster have
also been detected in hypertriglyceridemic subjects [13]. All
these observations indicate that the study of the apoA-I/C-
III/A-IV gene cluster is of major interest in relation to athero-
genesis.
We have recently generated transgenic (Tg) mice using a 33
kb human genomic fragment containing the entire cluster and
its 5P and 3P £anking regions [14]. These mice provide an
interesting model for studies of the regulation of the three
genes in combination. They are also useful for studies of the
function of the proteins encoded by the three genes. Expres-
sion of the entire human gene cluster induced hyperlipidemia
but reduced atherogenesis in genetically modi¢ed mice lacking
apoE [14]. The observed resistance to atherosclerosis could be
attributable to an enhanced RCT. RCT is the process by
which cholesterol in peripheral tissues is redistributed to sites
of excretion and metabolism, and is thought to be mediated
by HDL. The initial step in this process is the release of
unesteri¢ed cholesterol (UC) and phospholipid from the plas-
ma membrane of cells to acceptor particles. E¥ux of UC
occurs via a number of mechanisms, including: (i) aqueous
di¡usion to a phospholipid-containing acceptor, and (ii) e¥ux
to HDL mediated by receptors such as scavenger receptor
class B type I (SR-BI). The £ux of the UC between cells
and HDL is bi-directional; depending on the direction of
the UC concentration gradient between cells and lipoproteins,
either net e¥ux or net in£ux of cholesterol can occur. The
creation of a cholesterol gradient depends upon many proper-
ties of the acceptors and the cell plasma membrane. Such
factors include the cholesterol and phospholipid content and
the size and number of the acceptor particles. Another path-
way (iii) is the release of membrane phospholipid and choles-
terol to apolipoproteins. The identi¢cation of defects in the
ATP binding cassette transporter 1 (ABCA1) as the molecular
basis of Tangier disease [15] has highlighted its crucial role for
the loading of nascent apolipoprotein particles with phospho-
lipids and cholesterol. ApoA-I and apoA-IV have essential
roles in the reverse cholesterol pathway, mainly by their prop-
erty of forming small lipid-poor particles, characterized by
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their pre-L electrophoretic mobility, that are necessary to in-
teract with ABCA1 at the cell membranes.
To deepen our understanding of the properties developed
by the Tg mice, we decided to examine how an atherogenic
diet in£uences their characteristics. Atherosclerosis is a multi-
factorial process and environmental factors such as diet play
signi¢cant roles in its development. It is known that diets high
in saturated fat and cholesterol increase the risk of CHD
when administered to mice with a susceptible background
[16]. In the current study, we examined how a high fat-high
cholesterol diet (atherogenic diet) in£uences the expression of
the human apoA-I, C-III and A-IV genes, the plasma apo-
lipoprotein and lipid concentrations and the development of
aortic lesions in the Tg mice. We also analyzed the hepatic
expression of the SR-BI and ABCA1 genes, and the capacity
of the HDL and of the ds 1.21 g/ml density fraction from Tg
mice fed chow or the atherogenic diet to promote cholesterol
e¥ux from Fu5AH hepatoma cells [17] and from J774 macro-
phage cells [15,18,19].
2. Materials and methods
2.1. Animal models
Female Tg mice for the human apoA-I/C-III/A-IV gene cluster line
12 (10 weeks old) were used. Non-Tg littermates were used as con-
trols. Mice had free access for 20 weeks to a regular mouse chow
(UAR, France) or to a high fat-high cholesterol diet (chow diet sup-
plemented with 10% cocoa butter and 1.25% cholesterol (TD*8805;
Teklad Premier Laboratory Diets, Madison, WI, USA). Animals were
housed in a temperature-controlled room with alternating 12 h light
(7.00^19.00 h) and dark periods (19.00^7.00 h). All procedures involv-
ing animal handling and care were conducted in accordance with the
Pasteur Institute Guidelines for Husbandry of Laboratory Mice.
2.2. RNA analyses
Total RNAs were extracted from di¡erent tissues with RNA-plus
(Quantum), puri¢ed and electrophoresed on 1% agarose gels contain-
ing formaldehyde. Samples were blotted onto Hybond-N membranes
(Amersham Pharmacia Biotech), and hybridized with 32P-labeled
cDNA probes, as previously reported [14].
For SR-BI and ABCA1 mRNA analyses, total RNA was extracted
from livers by the acid guanidinium thiocyanate/phenol/chloroform
method [20]. Dot blot analysis was performed by loading 10 Wg of
total RNA onto Hybond C extra membranes (Amersham Pharmacia
Biotech). Membranes were hybridized using rodent SR-BI and
ABCA1 32P-labeled cDNA probes. A ubiquitin probe was used as
control. After 24 h exposure, spots were quanti¢ed on a GS525 phos-
phorimager. Values were normalized to the internal control probe and
expressed as a percent of control.
2.3. Plasma apolipoprotein quanti¢cation
Human apolipoproteins were quanti¢ed by immunoelectrophoresis
using speci¢c polyclonal antibodies (Hydragels SEBIA).
2.4. Plasma lipid analyses
Triglyceride concentrations were determined by an enzymatic GPO-
PAP method and total and HDL cholesterol concentrations were
determined by enzymatic CHOD-PAP methods with commercial
kits (Boehringer-Mannheim). Precinorm L was used as a calibrator.
2.5. Evaluation of atherosclerotic lesions
Fatty streak lesions were quanti¢ed in seven Tg and seven control
mice, by evaluating cross-sectional lesion sizes in the aortic sinus [21].
Procedures were as reported [14].
2.6. Lipoprotein fractionation
HDL and the fraction of density ds 1.21 g/ml used for cholesterol
e¥ux studies were obtained by sequential ultracentrifugation from
pooled mouse samples. HDL was isolated at d between 1.063 and
1.21 g/ml.
2.7. Cell culture and cholesterol e¥ux
2.7.1. Fu5AH cells. Cellular cholesterol e¥ux from Fu5AH rat
hepatoma cells to HDL was determined following the procedure de-
scribed by de la Llera Moya et al. [22]. Brie£y, the cells were main-
tained in minimal essential medium containing 5% fetal calf serum.
25 000 Fu5AH cells/ml were plated on 24 mm multiwell plates (Inbro,
Polylabo) using 2 ml/well. Two days after plating, cellular cholesterol
was labeled during a 72 h incubation with [3H]cholesterol (NEN,
Dupont de Nemours) (1 WCi/well). To allow equilibration of the label,
the cells were washed and incubated for 24 h in minimal essential
medium with 0.5% bovine serum albumin (BSA). Then, the cells
were washed with phosphate-bu¡ered saline (PBS) and incubated at
37‡C for 3 h with HDL at a protein concentration of 50 Wg/ml. At the
end of the incubation, the medium was removed and centrifuged; the
cell monolayer was washed three times with PBS and harvested with
0.5 ml of 0.1 M NaOH. Radioactivity was then measured in both
medium and cells, and the percentage of cholesterol e¥ux calculated.
All e¥ux values are averages of three determinations.
2.7.2. J774 macrophage cells. Cellular cholesterol e¥ux from J774
cells to poorly lipidated apolipoproteins was determined following the
procedure described by Fournier et al. [23]. Cells were maintained in
RPMI, containing 10% fetal calf serum. 150 000 cells/ml were plated
on 24 mm multiwell plates, using 2 ml/well. One day after plating,
cells were washed and cellular cholesterol labeled during a 48 h in-
cubation with [3H]cholesterol (NEN, Dupont de Nemours) (1 WCi/
well) in medium containing 2.5% BSA. On the day of the experiment,
con£uent cells were washed three times with PBS and incubated for 2 h
at 37‡C with RPMI containing 1% BSA to allow equilibration of the
[3H]cholesterol in the membranes. For determination of cholesterol
e¥ux, the cells were washed once with PBS and incubated at 37‡C
for 3 h with the plasma fraction of ds 1.21 g/ml at a protein concen-
tration equivalent to 0.2% dilution of plasma concentration. To
speci¢cally measure the cholesterol e¥ux, J774 macrophages were
pretreated, after the equilibration period, with 0.2 mmol/l 8-bromo-
cAMP for 12 h. All e¥ux values are averages of three determinations.
The rest of the procedure is the same as described for Fu5AH cells.
3. Results
The e¡ect of the high fat-high cholesterol diet on apoA-I/C-
III/A-IV Tg mice was determined in female mice fed a chow
or an atherogenic diet for 20 weeks.
3.1. Human apoA-I/C-III/A-IV transgene expression
We have previously shown that Tg mice fed a chow diet
expressed the three human genes in liver and intestine [14]. In
this report, Northern blot analyses indicated that feeding an
atherogenic diet resulted in an eightfold elevation of intestinal
apoA-I and apoC-III mRNA levels and a threefold elevation
of an intestinal apoA-IV mRNA level over those in Tg fed a
chow diet (Fig. 1B). The hepatic levels of the three apolipo-
protein mRNAs were diminished but the decrease was statis-
tically signi¢cant only for apoA-I mRNA (Fig. 1A).
3.2. Plasma apolipoprotein concentrations
Plasma concentrations of human apolipoproteins were ex-
amined by rocket immunoelectrophoresis using speci¢c anti-
bodies. The three human apolipoprotein concentrations were
Table 1
Human apolipoprotein concentrations in plasma of Tg mice after
an atherogenic diet
Chow diet Atherogenic diet
ApoA-I 199 þ 11 233 þ 12*
ApoC-III 5.4 þ 0.5 10.6 þ 1.0**
ApoA-IV 0.4 þ 0.1 9.7 þ 1.4**
Values are mean þ S.E.M. (n = 11) and expressed in mg/dl. *P6 0.05
and **P6 0.0001 vs. mice fed a chow diet.
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signi¢cantly higher in animals on an atherogenic diet, princi-
pally that of apoA-IV which was increased more than 20
times (Table 1).
3.3. Plasma lipid levels
When Tg mice were fed the atherogenic diet, triglyceride
levels dropped to 22% of the levels in chow diet Tg mice
(Table 2). In contrast, a sixfold increase in total cholesterol
concentration was observed, due mostly to an increase in the
non-HDL subclass. However, HDL cholesterol was also sig-
ni¢cantly raised (Table 2). In control littermate mice fed the
atherogenic diet, triglyceride levels remained low and only a
twofold increase in total cholesterol concentration, exclusively
in the non-HDL lipoproteins, was observed.
3.4. Diet-induced aortic lesions
We analyzed aortic lesions in Tg and control littermate
mice maintained on an atherogenic diet. Lesion scores in Tg
were reduced to 35% of those in control mice (10 104 þ 6364
Wm2 versus 29 498 þ 8086 Wm2 ; P6 0.0003).
3.5. Expression of SR-BI and ABCA1 genes
No signi¢cant di¡erences were observed in the mRNA lev-
els of both genes in Tg and non-Tg animals fed a chow diet.
An atherogenic diet provoked a signi¢cant increase in the
transcription of the two genes, but at similar levels in Tg
and control mice (Fig. 2A,B).
3.6. Cholesterol e¥ux studies
HDL from Tg mice maintained on an atherogenic diet was
more e⁄cient than HDL from non-Tg mice in promoting
cholesterol e¥ux from Fu5AH cells (Fig. 3A). Interestingly,
the phospholipid content of the HDL from the ¢rst group was
about 70% higher than that of the control group (data not
shown).
In the J774 mouse macrophage system, in the presence of
cAMP, the isolated fraction of ds 1.21 g/ml from Tg mice fed
an atherogenic diet was also more e⁄cient in promoting cho-
lesterol e¥ux than the fraction from control mice (Fig. 3B).
In both systems, cholesterol e¥ux was increased in Tg and
control mice fed an atherogenic diet, when compared to e¥ux
measured in Tg and control mice fed a chow diet (data not
shown).
4. Discussion
To study the e¡ect of the coordinated expression of the
three genes of the apoA-I/C-III/A-IV cluster, we recently gen-
erated Tg mice containing the human cluster. We have dem-
onstrated that expression of the entire cluster induces hyper-
lipidemia but protects against atherogenesis in mice in an
apoE-de¢cient background [14]. In the present report, we an-
alyze the e¡ect of this expression in mice in a normal genetic
background, when subjected to an induced atherogenic pro-
cess provoked by a high fat-high cholesterol diet. This diet
Fig. 1. Northern blot analysis. Quanti¢cation of the expression of the corresponding human mRNA in Tg mice fed a chow (open bars) or an
atherogenic (¢lled bars) diet in liver (A) and intestine (B). Values are reported as arbitrary units normalized to ubiquitin mRNA levels. Means
were obtained from RNA preparations from at least 5 di¡erent mice. *P6 0.05 and **P6 0.0001 vs. mice fed a chow diet.
Table 2
Lipid concentrations in control and Tg mice after an atherogenic diet
Triglycerides Total cholesterol HDL cholesterol
Chow diet Atherogenic diet Chow diet Atherogenic diet Chow diet Atherogenic diet
Control 69 þ 3 61 þ 7 75 þ 2 182 þ 30* 55 þ 3 55 þ 5
Transgenic 475 þ 5122 105 þ 7**2 115 þ 92 565 þ 69**22 74 þ 42 96 þ 6*22
Values are mean þ S.E.M. (n = 12) and expressed in mg/dl. *P6 0.05 and **P6 0.0001 vs. mice fed a chow diet. 2P6 0.05 and 22P6 0.0001 vs.
control mice.
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results in a clear elevation of intestinal apoA-I, apoC-III and
apoA-IV mRNA levels ; in contrast, the hepatic levels are
unmodi¢ed or decreased. These results indicate that lipids
up-regulate the intestinal expression of the three genes. This
is accompanied by an increased concentration of the corre-
sponding proteins in plasma. The increase is particularly sig-
ni¢cant in the case of apoA-IV in accordance with previous
observations indicating that apoA-IV plasma concentration in
rats and humans was enhanced after fat- or cholesterol-rich
diets [24^26].
In control mice fed an atherogenic diet, triglyceride levels
remained low, whereas total cholesterol concentration was
increased twofold, exclusively in the non-HDL lipoproteins.
In contrast, in Tg mice, triglyceride concentrations dropped
dramatically. This has also been observed in mouse apoA-IV
transgenic mice when fed an atherogenic diet [4]. In cluster Tg
mice, the cholesterol concentration was highly increased,
mainly in the non-HDL fraction, and less, although signi¢-
cantly, in the HDL population. These higher HDL cholesterol
levels, as well as the overexpression of the human gene cluster,
may have implications in the response of these animals to
diet-induced aortic lesions, and indeed we have found that
lesion scores in Tgs were reduced to 35% of those in control
mice.
ApoA-I and apoA-IV have been shown to protect against
the formation of aortic lesions, and both apolipoproteins par-
ticipate in RCT and promote cholesterol e¥ux from cultured
cells [23,27,28]. The initial step in the RCT process is the
release of free cholesterol and phospholipids from the cellular
plasma membrane to acceptor particles. Cholesterol e¥ux
from cells may occur by both SR-BI- and ABCA1-dependent
mechanisms [15,18,29]. It was previously observed that in SR-
BI Tg mice in an inbred mouse background hemizygous for a
human apoB transgene, endogenous SR-BI expression levels
were not a¡ected by a high fat-high cholesterol diet [30]. It
was also shown that ABCA1 mRNA levels were increased
upon cholesterol treatment of immortalized macrophages
and ¢broblasts [31]. In the present work we observed that in
the Tg and non-Tg animals fed a chow diet, hepatic mRNA
levels of the two SR-BI and ABCA1 genes were similar in
each case. It should be noted that an atherogenic diet pro-
vokes a signi¢cant but similar increase in the transcription of
the two genes, in both Tg and control mice. This seems to
indicate that the expression of the human apoA-I/C-III/A-IV
cluster in the mice has no in£uence on the transcription of the
genes encoding SR-BI and ABCA1.
E¥ux from Fu5AH hepatoma cells or from J774 macro-
phage cells was greater to Tg than to non-Tg acceptors in
mice fed an atherogenic diet. As phospholipid is a major
component of HDL that modulates cell cholesterol e¥ux, it
Fig. 2. Analyses of SR-BI (A) and ABCA1 (B) mRNAs in control
and Tg mice fed a chow (open bars) or an atherogenic (¢lled bars)
diet. Values are reported as arbitrary units normalized to ubiquitin
mRNA levels. Means were obtained from RNA preparations from
¢ve di¡erent mice from each type of sample. *P6 0.05 and
**P6 0.001 vs. mice fed a chow diet.
Fig. 3. A: E¥ux of [3H]cholesterol from Fu5AH to HDL from con-
trol (open bars) or Tg (¢lled bars) mice fed an atherogenic diet.
*P6 0.02 vs. control mice. Data are from a representative experi-
ment with triplicate wells (n = 3). Values are expressed as
mean þ S.D. B: E¥ux of [3H]cholesterol from J774 to particles of
ds 1.21 g/ml from control (open bars) or Tg (¢lled bars) mice fed a
chow or an atherogenic diet. *P6 0.035 vs. control mice. Data are
from a representative experiment with triplicate wells (n = 3). Values
are expressed as mean þ S.D. Values for control mice are taken as
100% to allow comparison.
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was interesting to observe that on an atherogenic diet the
phospholipid content of the Tg HDL was about 70% higher
than that of non-Tg mice. Thus, in the apoA-I/C-III/A-IV Tg
animals fed an atherogenic diet, cholesterol e¥ux is mediated
by phospholipid-rich HDL through the SR-BI receptor path-
way [32] and by the interaction between the lipid poor
ds 1.21 g/l fraction with the ABCA1 transporter [18].
As cholesterol e¥ux, the ¢rst step in RCT, is enhanced in
Tg mice, we can hypothesize that RCT is the basis of the
protective mechanism detected in these mice. However, at
least part of the protection against atherogenesis could also
be attributable to properties of apoA-I and apoA-IV unre-
lated to their role in RCT, such as their ability to protect
low density lipoprotein (LDL) from oxidative modi¢cation
[33,34]. It is interesting to note that in the Tg mice, after an
atherogenic diet, we detected a diminished level of autoanti-
bodies directed against oxidized LDL compared to that
present in normal counterparts; however, the di¡erence ob-
served was not statistically signi¢cant (data not shown).
In conclusion, here we present evidence that the human
apoA-I/C-III/A-IV gene cluster in Tg mice protects against
atherogenesis in response to an atherogenic diet. We have
previously observed such a protection in the Tg mice estab-
lished in an apoE-de¢cient background [14]. ApoA-I and
apoA-IV are known to have antiatherogenic properties,
whereas apoC-III overexpression resulted in increased athero-
sclerosis. Thus, the apoA-I/C-III/A-IV Tg mice provide a new
model for the design and screening of products that selectively
modulate the expression of the three human genes, in order to
favor the synthesis of apoA-I and/or apoA-IV.
Acknowledgements: This work was supported by the CNRS (FRE
2364), and by the EC (BMH4-CT97 2597). N.B. was a fellow of the
Fondation pour la Recherche Me¤dicale and of the Pasteur Institut
(Bourse Pasteur-Weizmann), M.A.O. is a fellow of the Pasteur Institut
(Bourse Pasteur-Weizmann). D.R. is a fellow of the Fundacion
Grande Cobian. We thank C. Lasselin and B. Derudas for excellent
technical assistance.
References
[1] Reichl, D. and Miller, N.E. (1989) Arteriosclerosis 9, 785^797.
[2] Karathanasis, S.K. (1985) Proc. Natl. Acad. Sci. USA 82, 6374^
6378.
[3] Miller, N.E. and Tall, A.R. (1992) Excerpta Medica, Amsterdam.
[4] Cohen, R.D., Castellani, L.W., Qiao, J.H., Van Lenten, B.J.,
Lusis, A.J. and Reue, K. (1997) J. Clin. Invest. 99, 1906^1916.
[5] Duverger, N., Tremp, G., Caillaud, J.M., Emmanuel, F., Castro,
G., Fruchart, J.C., Steinmetz, A. and Dene£e, P. (1996) Science
273, 966^968.
[6] Paszty, C., Maeda, N., Verstuyft, J. and Rubin, E.M. (1994)
J. Clin. Invest. 94, 899^903.
[7] Rubin, E.M., Krauss, R.M., Spangler, E.A., Verstuyft, J.G. and
Clift, S.M. (1991) Nature 353, 265^267.
[8] Ito, Y., Azrolan, N., O’Connell, A., Walsh, A. and Breslow, J.L.
(1990) Science 249, 790^793.
[9] Masucci-Magoulas, L., Goldberg, I.J., Bisgaier, C.L., Serajuddin,
H., Francone, O.L., Breslow, J.L. and Tall, A.R. (1997) Science
275, 391^394.
[10] Hayek, T., Masucci-Magoulas, L., Jiang, X., Walsh, A., Rubin,
E., Breslow, J.L. and Tall, A.R. (1995) J. Clin. Invest. 96, 2071^
2074.
[11] Karathanasis, S.K., Ferris, E. and Haddad, I.A. (1987) Proc.
Natl. Acad. Sci. USA 84, 7198^7202.
[12] Ordovas, J.M., Cassidy, D.K., Civeira, F., Bisgaier, C.L. and
Schaefer, E.J. (1989) J. Biol. Chem. 264, 16339^16342.
[13] Hong, S.H., Park, W.H., Lee, C.C., Song, J.H. and Kim, J.Q.
(1997) Clin. Chem. 43, 13^17.
[14] Vergnes, L., Baroukh, N., Ostos, M.A., Castro, G., Duverger,
N., Nanjee, M.N., Najib, J., Fruchart, J.C., Miller, N.E. and
Zakin, M.M. (2000) Arterioscler. Thromb. Vasc. Biol. 20,
2267^2274.
[15] Oram, J.F. and Vaughan, A.M. (2000) Curr. Opin. Lipidol. 11,
253^260.
[16] McNamara, D.J. (2000) Biochim. Biophys. Acta 1529, 310^320.
[17] Ji, Y., Jian, B., Wang, N., Sun, Y., Moya, M.L., Phillips, M.C.,
Rothblat, G.H., Swaney, J.B. and Tall, A.R. (1997) J. Biol.
Chem. 272, 20982^20985.
[18] Wang, N., Silver, D.L., Costet, P. and Tall, A.R. (2000) J. Biol.
Chem. 275, 33053^33058.
[19] Bortnick, A.E., Rothblat, G.H., Stoudt, G., Hoppe, K.L., Royer,
L.J., McNeish, J. and Francone, O.L. (2000) J. Biol. Chem. 275,
28634^28640.
[20] Chomczynski, P. and Sacchi, N. (1987) Anal. Biochem. 162, 156^
159.
[21] Paigen, B., Morrow, A., Holmes, P.A., Mitchell, D. and Wil-
liams, R.A. (1987) Atherosclerosis 68, 231^240.
[22] de la Llera Moya, M., Atger, V., Paul, J.L., Fournier, N., Moat-
ti, N., Giral, P., Friday, K.E. and Rothblat, G. (1994) Arterio-
scler. Thromb. 14, 1056^1065.
[23] Fournier, N., Atger, V., Paul, J.L., Sturm, M., Duverger, N.,
Rothblat, G.H. and Moatti, N. (2000) Arterioscler. Thromb.
Vasc. Biol. 20, 1283^1292.
[24] Green, P.H. and Glickman, R.M. (1981) J. Lipid Res. 22, 1153^
1173.
[25] Delamatre, J.G. and Roheim, P.S. (1983) Biochim. Biophys. Acta
751, 210^217.
[26] Bisgaier, C.L., Sachdev, O.P., Megna, L. and Glickman, R.M.
(1985) J. Lipid Res. 26, 11^25.
[27] Castro, G., Nihoul, L.P., Dengremont, C., de Geitere, C., Del£y,
B., Tailleux, A., Fievet, C., Duverger, N., Dene£e, P. and Fru-
chart, J.C. (1997) Biochemistry 36, 2243^2249.
[28] Duverger, N., Kruth, H., Emmanuel, F., Caillaud, J.M., Vigliet-
ta, C., Castro, G., Tailleux, A., Fievet, C., Fruchart, J.C. and
Houdebine, L.M. (1996) Circulation 94, 713^717.
[29] Gu, X., Kozarsky, K. and Krieger, M. (2000) J. Biol. Chem. 275,
29993^30001.
[30] Ueda, Y., Gong, E., Royer, L., Cooper, P.N., Francone, O.L.
and Rubin, E.M. (2000) J. Biol. Chem. 275, 20368^20373.
[31] Lawn, R.M., Wade, D.P., Garvin, M.R., Wang, X., Schwartz,
K., Porter, J.G., Seilhamer, J.J., Vaughan, A.M. and Oram, J.F.
(1999) J. Clin. Invest. 104, R25^31.
[32] Fournier, N., Paul, J.L., Atger, V., Cogny, A., Soni, T., de la
Llera-Moya, M., Rothblat, G. and Moatti, N. (1997) Arterio-
scler. Thromb. Vasc. Biol. 17, 2685^2691.
[33] Ostos, M.A., Conconi, M., Vergnes, L., Baroukh, N., Ribalta, J.,
Girona, J.M., Caillaud, A., Ochoa, A. and Zahin, M.M. (2001)
Arterioscler. Thromb. Vasc. Biol. (in press).
[34] Garner, B., Waldeck, A.R., Witting, P.K., Rye, K.A. and Stock-
er, R. (1998) J. Biol. Chem. 273, 6088^6095.
FEBS 25034 23-7-01
N. Baroukh et al./FEBS Letters 502 (2001) 16^2020
